Effectiveness of recently-approved oral antiviral medications on the outcome of patients with mild-to-moderate COVID-19 and pre–existing chronic obstructive …
Objectives This study assessed the effectiveness of the oral antiviral agents nirmatrelvir–
ritonavir (NMV-r) and molnupiravir (MOV) for treating mild-to-moderate coronavirus disease …
ritonavir (NMV-r) and molnupiravir (MOV) for treating mild-to-moderate coronavirus disease …
The effectiveness of novel oral antiviral treatment for non-hospitalized high-risk patients with COVID-19 during predominance of omicron XBB subvariants
Objectives This study investigated the association between nirmatrelvir plus ritonavir (NMV-
r) or molnupiravir and the outcomes of non-hospitalized high-risk patients with COVID-19 …
r) or molnupiravir and the outcomes of non-hospitalized high-risk patients with COVID-19 …
Comparative outcomes of SARS-CoV-2 primary and reinfection in older adult patients
Background The outcomes of older adult people acquiring SARS-CoV-2 reinfection was
unclear. This study aimed to compare the outcomes of older adult patients with COVID-19 …
unclear. This study aimed to compare the outcomes of older adult patients with COVID-19 …
[HTML][HTML] The effect of oral antiviral therapy for COVID-19 in managing non-hospitalized patients with lung cancer
Backgrounds The effectiveness of oral antiviral therapy including nirmatrelvir plus ritonavir
and molnupiravir in managing COVID-19 among individuals with pre-existing lung cancer …
and molnupiravir in managing COVID-19 among individuals with pre-existing lung cancer …
Clinical effectiveness of nirmatrelvir plus ritonavir on the short‐and long‐term outcome in high‐risk children with COVID‐19
This study investigated the clinical effectiveness of nirmatrelvir plus ritonavir (NMV‐r) on
short‐term outcome and the risk of postacute sequelae of severe acute respiratory syndrome …
short‐term outcome and the risk of postacute sequelae of severe acute respiratory syndrome …